The Potential Use of Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2013 Jan 12

PMID 23306700

Citations 47

Authors

Eun-Jung Kim

Nayoun Kim

Seok-Goo Cho

Affiliations

Soon will be listed here.

Abstract

In the last 10 years, mesenchymal stem cells (MSCs) have emerged as a therapeutic approach to regenerative medicine, cancer, autoimmune diseases, and many more due to their potential to differentiate into various tissues, to repair damaged tissues and organs, and also for their immunomodulatory properties. Findings in vitro and in vivo have demonstrated immune regulatory function of MSCs and have facilitated their application in clinical trials, such as those of autoimmune diseases and chronic inflammatory diseases. There has been an increasing interest in the role of MSCs in allogeneic hematopoietic stem cell transplantation (HSCT), including hematopoietic stem cell engraftment and the prevention and treatment of graft-versus-host disease (GVHD), and their therapeutic potential has been reported in numerous clinical trials. Although the safety of clinical application of MSCs is established, further modifications to improve their efficacy are required. In this review, we summarize advances in the potential use of MSCs in HSCT. In addition, we discuss their use in clinical trials of the treatment of GVHD following HSCT, the immunomodulatory capacity of MSCs, and their regenerative and therapeutic potential in the field of HSCT.

Citing Articles

Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model.

Gil S, Im K, Kim N, Lee J, Na H, Min G Int J Med Sci. 2024; 21(9):1649-1660.

PMID: 39006841 PMC: 11241100. DOI: 10.7150/ijms.93121.

Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities.

Kandeel M, Morsy M, Alkhodair K, Alhojaily S Biomolecules. 2023; 13(8).

PMID: 37627315 PMC: 10452295. DOI: 10.3390/biom13081250.

Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.

Taufiq H, Fakiruddin K, Muzaffar U, Lim M, Rusli S, Kamaluddin N Ther Adv Respir Dis. 2023; 17:17534666231158276.

PMID: 37128999 PMC: 10140776. DOI: 10.1177/17534666231158276.

Mesenchymal stroma/stem cells: Haematologists' friend or foe?.

Nachmias B, Zimran E, Avni B Br J Haematol. 2022; 199(2):175-189.

PMID: 35667616 PMC: 9796884. DOI: 10.1111/bjh.18292.

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy.

Sanmartin M, Borzone F, Giorello M, Yannarelli G, Chasseing N Front Bioeng Biotechnol. 2022; 10:882545.

PMID: 35497332 PMC: 9046597. DOI: 10.3389/fbioe.2022.882545.

References

Horwitz E, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini F . Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005; 7(5):393-5. DOI: 10.1080/14653240500319234. View

Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, Gustafsson J . Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia. 2007; 21(11):2271-6. DOI: 10.1038/sj.leu.2404833. View

Choi E, Shin I, Lee H, Park S, Park J, Nam M . Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med. 2011; 13(1):3-16. DOI: 10.1002/jgm.1531. View

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

Nadig S, Wieckiewicz J, Wu D, Warnecke G, Zhang W, Luo S . In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010; 16(7):809-13. PMC: 2929438. DOI: 10.1038/nm.2154. View

Erices A, Conget P, Minguell J . Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000; 109(1):235-42. DOI: 10.1046/j.1365-2141.2000.01986.x. View

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38(6):1745-55. PMC: 3021120. DOI: 10.1002/eji.200738129. View

English K, Ryan J, Tobin L, Murphy M, Barry F, Mahon B . Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009; 156(1):149-60. PMC: 2673753. DOI: 10.1111/j.1365-2249.2009.03874.x. View

10.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, CIVIDALLI G . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756-63. View

11.

Toma C, Pittenger M, Cahill K, Byrne B, Kessler P . Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105(1):93-8. DOI: 10.1161/hc0102.101442. View

12.

Teshima T . Th1 and Th17 join forces for acute GVHD. Blood. 2011; 118(18):4765-7. DOI: 10.1182/blood-2011-09-377325. View

13.

Gearhart J . New potential for human embryonic stem cells. Science. 1998; 282(5391):1061-2. DOI: 10.1126/science.282.5391.1061. View

14.

Pan B, Zeng L, Cheng H, Song G, Chen C, Zhang Y . Altered balance between Th1 and Th17 cells in circulation is an indicator for the severity of murine acute GVHD. Immunol Lett. 2012; 142(1-2):48-54. DOI: 10.1016/j.imlet.2011.12.005. View

15.

To L, Roberts M, Haylock D, Dyson P, Branford A, Thorp D . Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992; 9(4):277-84. View

16.

Thomas E, Storb R, Clift R, Fefer A, Johnson F, Neiman P . Bone-marrow transplantation (first of two parts). N Engl J Med. 1975; 292(16):832-43. DOI: 10.1056/NEJM197504172921605. View

17.

Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B . Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol. 2004; 32(7):657-64. DOI: 10.1016/j.exphem.2004.04.001. View

18.

Kessinger A, Smith D, Strandjord S, Landmark J, Dooley D, Law P . Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant. 1989; 4(6):643-6. View

19.

Asari S, Itakura S, Rawson J, Ito T, Todorov I, Nair I . Mesenchymal stem cells facilitate mixed hematopoietic chimerism induction and prevent onset of diabetes in nonobese diabetic mice. Pancreas. 2011; 40(6):846-54. PMC: 3138826. DOI: 10.1097/MPA.0b013e318215cdce. View

20.

Chan J, Tang K, Patel A, Bonilla L, Pierobon N, Ponzio N . Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006; 107(12):4817-24. PMC: 1895812. DOI: 10.1182/blood-2006-01-0057. View